Natera, Inc.

Natera, Inc. is a U.S.-based diagnostics company that develops and commercializes molecular testing products built on cell-free DNA and bioinformatics. Its tests are used across oncology, women’s health, and organ health, with operations centered in the United States and supported by laboratory partners and select international distribution arrangements.

−11,6 %

−9,0 %

+35,9 %

3.39

3.24

— Natera, Inc.
%
Oncology testing45% Blood-based molecular tests used to detect and monitor cancer, including MRD applications.
Women’s health testing35% Prenatal and reproductive genetic tests sold through direct and partner channels.
Organ health testing15% Transplant-related tests used to assess organ rejection and post-transplant monitoring.
Licensing and partner-enabled testing5% Cloud-based Constellation licensing and third-party laboratory workflows.

Natera sells to insurers, clinics, physician practices, medical centers, independent laboratories, reference...

  • Third-party payers and insurersprimary

    They reimburse Panorama, Horizon, Signatera and other tests under in-network contracts, enabling scale and predictable pricing.

  • Clinics, physician practices and medical centersprimary

    They order screening and diagnostic tests for patients in women’s health, oncology and organ health.

  • Laboratory partners and distribution partnerssecondary

    They distribute or run tests under partner and licensing models, extending market reach.

  • Research laboratories and pharmaceutical companiessecondary

    They buy clinical trial testing and related services for development and research programs.

Natera’s revenue base is overwhelmingly U.S.-centric, with the company disclosing that 95% of revenue came from U.S...

  • •United States is the core market and main revenue source
  • •U.S. direct sales force drives most commercial activity
  • •U.S. laboratory partners add incremental distribution reach
  • •International sales are small but include partner channels
  • •Foreign currency exposure is mainly euros and Singapore dollars

Natera’s strategy centers on expanding adoption of its core tests, especially Panorama, Horizon and Signatera, through...

01
Increase U.S. market penetrationshort-term

Most revenue comes from the U.S., so deeper adoption drives scale and commercial leverage.

02
Strengthen reimbursement and payer coverageshort-term

In-network coverage improves predictability and expands the addressable patient base.

03
Broaden product and evidence basemedium-term

Clinical validation and new products support adoption across oncology, women’s health and organ health.

04
Extend partner and licensing channelsmedium-term

Partnerships can expand geographic reach and laboratory access without building every channel directly.

Natera depends heavily on reimbursement, payer coverage and continued adoption of a small number of core tests, so...

high

Reimbursement and coverage risk

A large share of revenue depends on insurer coverage and in-network pricing for tests.

Scope
Panorama, Horizon, Signatera
Materiality
high
high

Product concentration risk

The company says most revenue comes from a few core tests, so weakness in one can affect the whole business.

Scope
Panorama NIPT, Horizon carrier screening, Signatera
Materiality
high
high

Intellectual property litigation

The molecular diagnostics field is patent-intensive and the company is involved in disputes with competitors.

Scope
Oncology, women’s health and organ health assays
Materiality
high
high

Single-source supply dependence

Validated sequencing platform and reagent supply concentration can disrupt test operations if interrupted.

Scope
Illumina sequencing platform and related reagents
Materiality
high
medium

Third-party partner dependence

Laboratory partners and distributors can reduce control over commercialization, pricing and market access.

Scope
Women’s health distribution and international partnerships
Materiality
medium
medium

Data privacy and cybersecurity

Patient data may be handled by vendors, licensees and cloud systems, creating breach and compliance risk.

Scope
Cloud-based Constellation model and third-party vendors
Materiality
medium
Revenue recognition
Direct patient/insurer billing, partner billing and Constellation licensing
Stock-based compensation
Non-cash compensation expense
Fair value of acquired intangibles
Developed technology intangible assets
Foreign currency remeasurement
Euro and Singapore dollar exposure
Contingencies and legal proceedings
Patent infringement and partner disputes

Septerna, Inc.

SEPN · Pharmaceutical Preparations

DANAHER CORP /DE/

DHR · Industrial Instruments For Measurement, Display, and Control

Sotera Health Co

SHC · Services-Misc Health & Allied Services, NEC

BIOMERICA INC

BMRA · In Vitro & In Vivo Diagnostic Substances

Azitra, Inc.

AZTR · Pharmaceutical Preparations

VERACYTE, INC.

VCYT · Services-Medical Laboratories

: 29/04/2026